ArticleAutoimmune diseases2011
Myasthenia gravis: a review of available treatment approaches.
Article in Autoimmune diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.Journal of neurology · 2021Pooled it
- Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study.Journal of neurology · 2025Trial
- Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population.PloS one · 2012Trial
- What Patients Don't Say and Physicians Don't Ask: A Needs Assessment in Myasthenia Gravis Integrating Patient and Healthcare Professional Perspectives.Neurology and therapy · 2025Article
- Update on thymic epithelial tumors: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions.Aging and disease · 2023Article
- Detection of Antibodies against the Acetylcholine Receptor in Patients with Myasthenia Gravis: A Comparison of Two Enzyme Immunoassays and a Fixed Cell-Based Assay.Journal of clinical medicine · 2023Article
- Choices and Challenges With Treatment of Myasthenia Gravis in Pregnancy: A Systematic Review.Cureus · 2023Review
- Observational
- miRNAs as the important regulators of myasthenia gravis: involvement of major cytokines and immune cells.Immunologic research · 2023Review
- Clinical features and outcomes of patients with myasthenia gravis admitted to an intensive care unit: A 20-year retrospective study.The Southern African journal of critical care : the official journal of the Critical Care Society · 2023Article
- Exploring the Gut Microbiome in Myasthenia Gravis.Nutrients · 2022Review
- Factors affecting the intention of COVID-19 vaccination in Korean patients with myasthenia gravis: A survey-based study.Frontiers in neurology · 2022Article
- Myasthenia gravis associated with novel coronavirus 2019 infection: A report of three cases.Clinical neurology and neurosurgery · 2021Article
- Review
- Thymoma complicated with myasthenia gravis and Good syndrome - a therapeutic conundrum: a case report.Journal of medical case reports · 2019Article
- Dose-dependent inhibition of demyelination and microglia activation by IVIG.Annals of clinical and translational neurology · 2016Article
- Potential Health Risks Posed by Plant-Derived Cumulative Neurotoxic Bufadienolides in South Africa.Molecules (Basel, Switzerland) · 2016Article
- Myasthenia Gravis Presenting as Persistent Unilateral Ptosis with Facial Droop.The Journal of emergency medicine · 2015Article
- Anti-MuSK-positive myasthenia gravis diagnosed during pregnancy: new challenges for an old disease?BMJ case reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with autoimmune myasthenia gravis (MG) should be further classified before initiating therapy, as treatment response varies for ocular versus generalised, early onset versus late onset, and acetylcholine receptor antibody positive versus MuSK antibody positive disease. Most patients need immunosuppression in addition to symptomatic therapy. Prednisolone and azathioprine represent first choice drugs, whereas several second choice options are recommended and should be considered. Thymectomy should be undertaken in MG with thymoma and in generalised, early-onset MG. For MG crises and other acute exacerbations, intravenous immunoglobulin (IvIg) and plasma exchange are equally effective and safe treatments. Children and females in child bearing age need special attention regarding potential side effects of immunosuppressive therapy. MG pathogenesis is known in detail, but the immune therapy is still surprisingly unspecific, without a pin-pointed attack on the defined disease-inducing antigen-antibody reaction being available.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.